CN115068452B - Application of aloe-emodin in preparing medicine for preventing and treating African swine fever - Google Patents

Application of aloe-emodin in preparing medicine for preventing and treating African swine fever Download PDF

Info

Publication number
CN115068452B
CN115068452B CN202210256584.3A CN202210256584A CN115068452B CN 115068452 B CN115068452 B CN 115068452B CN 202210256584 A CN202210256584 A CN 202210256584A CN 115068452 B CN115068452 B CN 115068452B
Authority
CN
China
Prior art keywords
aloe
emodin
swine fever
african swine
asfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210256584.3A
Other languages
Chinese (zh)
Other versions
CN115068452A (en
Inventor
王湘如
刘慧�
国师榜
陈启超
张逸博
刘占悝
李亮
陈焕春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huazhong Agricultural University
Original Assignee
Huazhong Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huazhong Agricultural University filed Critical Huazhong Agricultural University
Priority to CN202210256584.3A priority Critical patent/CN115068452B/en
Publication of CN115068452A publication Critical patent/CN115068452A/en
Application granted granted Critical
Publication of CN115068452B publication Critical patent/CN115068452B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses an application of aloe-emodin in preparing a medicine for preventing and treating African swine fever, and belongs to the field of veterinary medicines. The aloe-emodin has remarkable protective effect on cells infected with African swine fever virus, has remarkable anti-African swine fever virus activity and is in a dose-dependent relationship. The aloe-emodin can be used as an active ingredient for preparing a novel medicine for preventing and treating African swine fever, and has wide application prospect.

Description

Application of aloe-emodin in preparing medicine for preventing and treating African swine fever
Technical Field
The invention belongs to the field of veterinary medicines, and particularly relates to application of aloe-emodin in preparation of medicines for preventing and treating African swine fever.
Background
African swine fever (African swine fever, ASF) is an epidemic infectious disease caused by African swine fever virus (African swine fever virus, ASFV). First in kennia in the eastern africa in the 20 th century, and later spread to europe, south america, asia, etc.
Aloe-emodin is an anthraquinone compound extracted from aloe leaves, is an active ingredient of many Chinese herbal medicines, such as rheum officinale, aloe and semen cassiae, and has been found to have many pharmacological activities, such as anti-tumor, anti-oxidation, anti-cancer and anti-angiogenesis. In addition, aloe-emodin has also been shown to have a broad antiviral effect. The chemical name of aloe-emodin is 1.8-dihydroxy-3-hydroxymethyl anthraquinone, and the molecular formula is as follows: c (C) 15 H 10 O 5 Relative molecular mass: 270.2369 the chemical structural formula of aloe-emodin is as follows.
At present, research reports on the anti-African swine fever virus effect of aloe-emodin are not found, and related patents are not found.
Disclosure of Invention
The invention surprisingly discovers that the natural product aloe-emodin can obviously inhibit the expression of ASFV structural protein p30, thereby preventing viruses from infecting host cells and playing a role in inhibiting ASFV infection.
The invention aims to provide an application of aloe-emodin as a natural product in preparing an ASFV-resisting medicament and an African swine fever-preventing medicament.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
firstly, detecting toxicity of aloe-emodin to Pig Alveolar Macrophages (PAM) by using a CCK-8 (Cell Counting Kit-8) method, and determining the safe working concentration of the aloe-emodin. Subsequently, the protective effect of aloe-emodin on PAM cells infected with ASFV was evaluated using the established ASFV cell infection model. The evaluation mode is mainly fluorescence quantitative PCR (qPCR) test and half red blood cell adsorption (HAD) 50 ) Assays, indirect Immunofluorescence (IFA) assays, western Blot (Western Blot) assays, and the like.
The invention discovers that aloe-emodin has lower cytotoxicity through in vitro cytotoxicity test, and half of cytotoxicity dose (CC 50 ) 15.5. Mu.M.
According to the invention, through in vitro cell experiments, aloe-emodin has remarkable functions of inhibiting the expression of ASFV structural protein p30 and inhibiting the replication of ASFV, and the inhibition effect is enhanced along with the increase of the drug concentration. Half-dose effective against ASFV (IC) in aloe-emodin in vitro cell assay 50 ) 1.1. Mu.M.
The invention provides an application of natural aloe-emodin or pharmaceutically acceptable salt thereof in preparing an anti-ASFV medicament and an application in preparing a medicament for preventing and treating African swine fever.
The invention provides an application of a pharmaceutical preparation prepared by taking aloe-emodin or pharmaceutically acceptable salt thereof as an effective ingredient and adding an auxiliary agent in resisting ASFV or preventing and treating African swine fever.
The pharmaceutical preparation is any veterinary clinically acceptable dosage form such as injection, powder, granule, tablet and the like.
The invention has the following advantages for preventing and treating African swine fever:
1. the aloe-emodin has stronger inhibitory activity on ASFV in vitro and also has remarkable ASFV-resisting activity at the concentration of 1.1 mu M, which indicates that the aloe-emodin has high-efficiency ASFV-resisting effect.
2. Aloe-emodin has low cytotoxicity and half cytotoxicity dose (CC in vitro cytotoxicity test 50 ) At 15.5 μm, a lower cytotoxic effect was only shown at more than 10 times higher than the effective concentration.
3. Aloe-emodin is a natural product widely existing in nature, and raw materials are widely available and low in cost; the preparation method is safe and reliable, and has great potential value in developing new drugs for preventing and treating African swine fever.
Drawings
FIG. 1 is a cytotoxicity assay of aloe-emodin on PAM cells using CCK-8 assay at various concentrations;
FIG. 2 is a graph showing the effect of qPCR on aloe-emodin on ASFV proliferation in PAM cells;
FIG. 3 is a method using an HAD 50 Determining the effect of aloe-emodin on ASFV titer in PAM cells;
FIG. 4 is a Western Blot analysis of the effect of aloe-emodin on ASFV p30 protein expression in PAM cells;
FIG. 5 is a graph showing the effect of aloe-emodin on ASFV p30 protein expression in PAM cells using IFA.
Detailed Description
In order to make the technical means, the creation characteristics, the purpose and the effects of the present invention easy to be clarified, the present invention is further described with reference to the following specific embodiments, but the scope of the present invention is not limited to the following embodiments.
The following experiments were all given biosafety and african swine fever laboratory activity permissions:
the animal biosafety third-level laboratory (ABSL-3) of China agricultural university has obtained the license of the agricultural rural department on developing African swine fever pathogen research and has been filed in the agricultural rural department, and meets the requirements of national biosafety level.
The reagents used in the experiments were all common commercial reagents unless otherwise specified; the methods of operation in the experiments are known in the art unless otherwise specified. The ASFV used in the following examples is a genotype II ASFV.
Example 1: cytotoxicity test of aloe-emodin with different concentrations on PAM cells by CCK-8 method
At 1.5×10 per well 5 PAM cells were inoculated into 96-well cell plates and cultured in a 37℃cell incubator, after the cells were completely adherent, aloe-emodin was diluted in a gradient with 1640 medium containing 2% serum, and added to the cells, with 3 multiple wells per aloe-emodin concentration. After 72h incubation in a 37℃cell incubator, the cell culture medium was discarded under light-protected conditions, and 100. Mu.L of serum-free 1640 medium and 10. Mu.L of CCK-8 solution (Biyunshan) were added to each well. After further incubation for 0.5h in the cell incubator, absorbance at a wavelength of 450nm was determined using a microplate reader. As can be seen from FIG. 1, aloe-emodin has a PAM cell viability of 50% at a concentration of 15. Mu.M.
Example 2: qPCR determination of the effect of aloe-emodin on ASFV proliferation in PAM cells
At 1.5×10 per well 5 PAM cells were inoculated into 96-well cell plates and cultured in a 37℃cell incubator, after the cells were completely adherent, aloe-emodin was diluted in gradient with 1640 medium containing 2% serum, aloe-emodin and virus (MOI=0.1) were added together into the cells, 3 duplicate wells were set for each aloe-emodin concentration, and placed in a 37℃incubator for culture. And (3) collecting a virus sample after 72h, repeatedly freezing and thawing for 3 times at-80 ℃, extracting a virus genome, detecting the copy number of the virus by qPCR, and calculating the inhibition ratio of aloe-emodin to the virus by using a primer in reference to the group standard 'African swine fever virus real-time fluorescence PCR detection method' T/CVMA 5-2018.
As shown in FIG. 2, aloe-emodin of the present invention has significant inhibitory effect on ASFV at concentrations ranging from 1.25 μm to 10. Mu.M, and exhibits dose dependence.
Example 3: half-red blood cell adsorption (HAD) 50 ) Determination of the Effect of aloe-emodin, a Natural product, on ASFV titres in PAM cells
At each hole 10 6 PAM cells were inoculated into 24-well cell plates and cultured in a 37℃cell incubator, after the cells were completely adherent, the natural product was diluted in a gradient with 1640 medium containing 2% serum, and a mixed solution of aloe-emodin and virus (MOI=0.1), which was a natural product, was added to the cells and placed in the 37℃incubator for culture. Collecting virus sample after 72 hr, repeatedly freezing and thawing at-80deg.C for 3 times, and diluting to 10 times -10 Dilutions were added to the cell plates, followed by 20 μl of 1% porcine red blood cell suspension per well. The cells were incubated in a 37℃incubator for 7 days, and the agglutination of the erythrocytes was observed daily. Calculation of the half-erythrocyte adsorption dose (HAD) of the virus 50 ) The method is a Reed-Muench two-step method.
As shown in FIG. 3, the aloe-emodin of the present invention has a remarkable inhibitory effect on the viral titer of ASFV infected with PAM cells at a concentration of 1.25 μm to 20. Mu.M, and exhibits remarkable dose dependence.
Example 4: western Blot analysis of the effect of aloe-emodin on ASFV p30 protein expression in PAM cells
At 5X 10 per well 6 PAM cells were inoculated into 6-well cell plates and cultured in a 37 ℃ cell incubator, after the cells were completely adherent, aloe-emodin was diluted in gradient with 1640 medium containing 2% serum, and a mixed solution of aloe-emodin and virus (moi=0.1) was added to the cells. Placing in a 37 ℃ incubator for culturing for 48 hours, discarding culture supernatant, washing with PBS for 2 times, adding 200 mu L of Western Blot cell lysate into each hole, ice-bathing for 15 minutes, collecting lysate, centrifuging at 4 ℃ for 15 minutes at 1200rpm, collecting supernatant, and carrying out Western Blot detection on ASFV p30 protein and beta-actin internal reference protein stripsA belt.
As shown in FIG. 4, the aloe-emodin of the present invention has a remarkable inhibitory effect on ASFV p30 protein expression of PAM-infected cells at a concentration of 2.5 μm-20. Mu.M, and exhibits remarkable dose dependence.
Example 5: IFA analysis of the effect of aloe-emodin on ASFV p30 protein expression in PAM cells
At each hole 10 6 PAM cells were inoculated into 24-well cell plates and cultured in a 37 ℃ cell incubator, after the cells were completely adherent, aloe-emodin was diluted in gradient with 1640 medium containing 2% serum, and a mixed solution of aloe-emodin and virus (moi=0.1) was added to the cells. After placing in a 37 ℃ incubator for culturing for 72 hours, the culture solution in the 96-well plate is discarded, and PBS solution is used for gently 1-2 times. 200 μl of 4% paraformaldehyde tissue fixative was added, the mixture was fixed at room temperature for 30min, the fixative was discarded, and the solution was washed 3 times with PBS for 5min each. 200. Mu.L of 0.1% Triton X-100 was added, left at room temperature for 20min, the solution was discarded, and washed 3 times with PBS solution. 200. Mu.L of 5% BSA solution was added, incubated at 37℃for 1h, the blocking solution was discarded and washed 3 times with PBS solution. ASFV p30 antibody was diluted 1:200, 200. Mu.L per well, incubated for 1h at 37℃and washed 3 times with PBS. FITC-labeled goat anti-pig fluorescent antibody was diluted to 5. Mu.g/mL, 200. Mu.L was added to each well, incubated at 37℃for 1h in the dark, and washed 3 times with PBS under the dark condition. Adding anti-fluorescence quenching sealing liquid, measuring fluorescence value by using a multifunctional enzyme label instrument, and observing fluorescence under a fluorescence microscope.
As shown in FIG. 5, the aloe-emodin of the present invention has a remarkable inhibitory effect on ASFV p30 protein expression of PAM-infected cells at a concentration of 1.25 μm-10. Mu.M, and exhibits remarkable dose dependence.

Claims (4)

1. Application of aloe-emodin or pharmaceutically acceptable salt thereof in preparing medicine for resisting African swine fever virus is provided.
2. Application of aloe-emodin or pharmaceutically acceptable salt thereof in preparing medicine for preventing and treating African swine fever is provided.
3. Use according to claim 1 or 2, characterized in that: the aloe-emodin or pharmaceutically acceptable salt thereof is used as an effective ingredient and auxiliary agents are used for preparing the pharmaceutical preparation.
4. A use according to claim 3, characterized in that: the pharmaceutical preparation comprises injection, powder, granule and tablet.
CN202210256584.3A 2022-03-16 2022-03-16 Application of aloe-emodin in preparing medicine for preventing and treating African swine fever Active CN115068452B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210256584.3A CN115068452B (en) 2022-03-16 2022-03-16 Application of aloe-emodin in preparing medicine for preventing and treating African swine fever

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210256584.3A CN115068452B (en) 2022-03-16 2022-03-16 Application of aloe-emodin in preparing medicine for preventing and treating African swine fever

Publications (2)

Publication Number Publication Date
CN115068452A CN115068452A (en) 2022-09-20
CN115068452B true CN115068452B (en) 2023-12-12

Family

ID=83247453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210256584.3A Active CN115068452B (en) 2022-03-16 2022-03-16 Application of aloe-emodin in preparing medicine for preventing and treating African swine fever

Country Status (1)

Country Link
CN (1) CN115068452B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797184A (en) * 2021-07-22 2021-12-17 华南农业大学 Application of daneserin in preparation of drug for preventing and treating African swine fever virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797184A (en) * 2021-07-22 2021-12-17 华南农业大学 Application of daneserin in preparation of drug for preventing and treating African swine fever virus

Also Published As

Publication number Publication date
CN115068452A (en) 2022-09-20

Similar Documents

Publication Publication Date Title
Ghannad et al. The effect of aqueous extract of Glycyrrhiza glabra on herpes simplex virus 1
CN112791084B (en) New application of ML-60218 in preparation of drugs for treating African swine fever
CN113813269B (en) Application of Perifosine in preparation of anti-Hantaan virus medicine
WO2023273558A1 (en) Use of exocarpium citri grandis productive cough extract in preparation of drug for inhibiting human coronavirus infection
CN115068452B (en) Application of aloe-emodin in preparing medicine for preventing and treating African swine fever
Nishijima et al. Detection of anti-feline infectious peritonitis virus activity of a Chinese herb extract using geneLEAD VIII, a fully automated nucleic acid extraction/quantitative PCR testing system
CN111803472A (en) Novel coronavirus resistant medicine and application thereof
CN108721293A (en) Application of the ipecine in preparing wide spectrum anti-coronavirus drug
CN114652731B (en) Application of tannic acid in preparation of medicine for preventing and treating African swine fever
CN113143927B (en) Application of naphthoquine phosphate in preparation of medicine for treating diseases caused by viruses
CN105853406B (en) Application of procyanidine in preparation of medicine for preventing and treating porcine reproductive and respiratory syndrome
CN115137762B (en) Cyclocarya paliurus extract and application thereof in preparation of anti-coronavirus drugs
CN114246859A (en) Application of andrographolide in preparing product for treating coronavirus infection
CN115400121B (en) Application of SNX-2112 in preparation of medicines for resisting adenovirus infection
CN114652727B (en) Application of WYE-125132 in preparation of medicine for resisting adenovirus infection
Chen et al. Inhibitory role of baicalin on human herpes virus type 6 in vitro
CN115400120B (en) Application of Alvesbimycin in preparation of medicine for resisting adenovirus infection
CN112675211B (en) Cyclocarya paliurus extract and application thereof in preparation of anti-coronavirus medicines
CN115006395B (en) Application of XL888 in preparation of medicine for resisting adenovirus infection
CN113750083B (en) Application of metformin in preparation of medicine for treating hand-foot-and-mouth disease
CN118286196B (en) Application of salvianolic acid A in preparation of anti-bovine nodular skin disease virus drugs
CN115120594B (en) Application of Zelavespib in preparation of medicine for resisting adenovirus infection
CN116098893B (en) Application of compound Thapsigargin in preparation of medicines for preventing or treating porcine epidemic diarrhea
CN115590873B (en) Application of baicalin in preparation of anti-pseudorabies virus medicine
CN114767687B (en) Application of Sapanisertib in preparation of medicine for resisting adenovirus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant